Suhn Kyong Rhie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suhn Kyong Rhie has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Peggy J. Farnham
Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
13 shared publications Chenghao Zhu
8 shared publicationsJonathan L. Wright
8 shared publications- Julie Livingstone
Department of Human Genetics, University of California, Los Angeles, Los Angeles, USA
8 shared publications - Kristina M. Jordahl
Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
8 shared publications - Paul C. Boutros
Department of Human Genetics, University of California Los Angeles
8 shared publications
Latest Publications
- Open Access
A single epigenetic repressor controls opposing developmental tempos in human neural and cranial neural crest lineages
Summary: The precise timing of lineage specification is essential for embryonic development, yet the epigenetic mechanisms enforcing human developmental tempo remain poorly understood 1,2 . Heterozygous loss-of-function variants in ZNF462 cause Weiss-Kruszka syndrome (WKS), a pleiotropic disorder characterized by neurodevelopmental delays and craniofacial dysmorphisms 3–5 . Here, we show that ZNF462 acts as an epigenetic gatekeeper that coordinates human developmental tempo across divergent lineages by repressing cell lineage-specific gene enhancers. In human embryonic stem cells (hESCs), ZNF462 maintains self-renewal by recruiting the G9A/GLP histone methyltransferase complex to silence primate-specific retrotransposon-derived enhancers. Upon neural lineage commitment, ZNF462 redirects to hominoid-specific LTR5_Hs elements and divergent lineage-specific enhancer programs, where its loss produces opposing kinetics. In neural progenitor cells (NPCs), ZNF462 enforces G9A/GLP-dependent repression of ZIC-driven neural enhancers, and loss of this repression traps NPCs in a progenitor state, slowing cortical neurogenesis without impairing terminal neurogenic capacity. In neural crest cells (NCCs), ZNF462 targets repressive chromatin to silence SOX9 family-driven enhancers. Here, ZNF462 haploinsufficiency triggers premature activation of definitive NCC specifiers, accelerating differentiation. These findings establish that a single repressor can simultaneously decelerate and accelerate developmental tempo by gating lineage-specific enhancers, placing Weiss-Kruszka syndrome into the emerging class of human developmental timing disorders.
Open AccessA single epigenetic repressor controls opposing developmental tempos in human neural and cranial neural crest lineages
Summary: The precise timing of lineage specification is essential for embryonic development, yet the epigenetic mechanisms enforcing human developmental tempo remain poorly understood 1,2 . Heterozygous loss-of-function variants in ZNF462 cause Weiss-Kruszka syndrome (WKS), a pleiotropic disorder characterized by neurodevelopmental delays and craniofacial dysmorphisms 3–5 . Here, we show that ZNF462 acts as an epigenetic gatekeeper that coordinates human developmental tempo across divergent lineages by repressing cell lineage-specific gene enhancers. In human embryonic stem cells (hESCs), ZNF462 maintains self-renewal by recruiting the G9A/GLP histone methyltransferase complex to silence primate-specific retrotransposon-derived enhancers. Upon neural lineage commitment, ZNF462 redirects to hominoid-specific LTR5_Hs elements and divergent lineage-specific enhancer programs, where its loss produces opposing kinetics. In neural progenitor cells (NPCs), ZNF462 enforces G9A/GLP-dependent repression of ZIC-driven neural enhancers, and loss of this repression traps NPCs in a progenitor state, slowing cortical neurogenesis without impairing terminal neurogenic capacity. In neural crest cells (NCCs), ZNF462 targets repressive chromatin to silence SOX9 family-driven enhancers. Here, ZNF462 haploinsufficiency triggers premature activation of definitive NCC specifiers, accelerating differentiation. These findings establish that a single repressor can simultaneously decelerate and accelerate developmental tempo by gating lineage-specific enhancers, placing Weiss-Kruszka syndrome into the emerging class of human developmental timing disorders.
- Open Access
- 23 July 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1) , 230
Decoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer
The transcription process is controlled by non-coding regulatory elements, more than 70% of which are putative enhancers. These enhancers comprise over 600
- 23 July 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1) , 230
Open AccessDecoding 3D chromatin architecture reveals distinct enhancer classes underlying hierarchical gene regulation in prostate cancer
The transcription process is controlled by non-coding regulatory elements, more than 70% of which are putative enhancers. These enhancers comprise over 600
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Background:Patients with prostate cancer experience heterogeneous outcomes after radical prostatectomy. Genomic studies including The Cancer Genome Atlas (TCGA) have reported molecular signatures of prostate cancer, but few studies have assessed the prognostic effects of DNA methylation profiles.Methods:We conducted the largest methylome subtyping analysis for primary prostate tumors to date, using methylome data from three patient populations: TCGA, a prostate cancer cohort study conducted at the Fred Hutchinson Cancer Research Center (FH; Seattle, WA), and the Canadian International Cancer Genome Consortium (ICGC) cohort. Four subtypes were detected in the TCGA dataset, then independently assigned to FH and ICGC cohort data. The identified methylation subtypes were assessed for association with cancer prognosis in the above three patient populations.Results:Using a set of hypermethylated CpG sites, four methylation subtypes were identified in TCGA. Compared with subtype 1, subtype 4 had an HR of 2.09 (P = 0.029) for biochemical recurrence (BCR) in TCGA patients. HRs of 2.76 (P = 0.002) for recurrence and 9.73 (P = 0.002) for metastatic-lethal (metastasis or prostate cancer–specific death) outcomes were observed in the FH cohort. A similar pattern of association was noted in the Canadian ICGC cohort, though HRs were not statistically significant.Conclusions:A hypermethylated subtype was associated with an increased hazard of recurrence and mortality in three studies with prostate tumor methylome data. Further molecular work is needed to understand the effect of methylation subtypes on cancer prognosis.Impact:This study identified a DNA methylation subtype that was associated with worse prostate cancer prognosis after radical prostatectomy.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Background:Patients with prostate cancer experience heterogeneous outcomes after radical prostatectomy. Genomic studies including The Cancer Genome Atlas (TCGA) have reported molecular signatures of prostate cancer, but few studies have assessed the prognostic effects of DNA methylation profiles.Methods:We conducted the largest methylome subtyping analysis for primary prostate tumors to date, using methylome data from three patient populations: TCGA, a prostate cancer cohort study conducted at the Fred Hutchinson Cancer Research Center (FH; Seattle, WA), and the Canadian International Cancer Genome Consortium (ICGC) cohort. Four subtypes were detected in the TCGA dataset, then independently assigned to FH and ICGC cohort data. The identified methylation subtypes were assessed for association with cancer prognosis in the above three patient populations.Results:Using a set of hypermethylated CpG sites, four methylation subtypes were identified in TCGA. Compared with subtype 1, subtype 4 had an HR of 2.09 (P = 0.029) for biochemical recurrence (BCR) in TCGA patients. HRs of 2.76 (P = 0.002) for recurrence and 9.73 (P = 0.002) for metastatic-lethal (metastasis or prostate cancer–specific death) outcomes were observed in the FH cohort. A similar pattern of association was noted in the Canadian ICGC cohort, though HRs were not statistically significant.Conclusions:A hypermethylated subtype was associated with an increased hazard of recurrence and mortality in three studies with prostate tumor methylome data. Further molecular work is needed to understand the effect of methylation subtypes on cancer prognosis.Impact:This study identified a DNA methylation subtype that was associated with worse prostate cancer prognosis after radical prostatectomy.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Table from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
Supplementary Figure from Methylation Subtypes of Primary Prostate Cancer Predict Poor Prognosis
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (8)
Tracing regulatory element networks using epigenetic traits to identify key transcription factors: TENET R/Bioconductor package
Summary: There is a lack of publicly available bioinformatic tools that can be widely used by researchers to identify transcription factors (TFs) that regulate cell type-specific regulatory elements (REs). To address this, we developed the Tracing regulatory Element Networks using Epigenetic Traits (TENET) R/Bioconductor package. By collecting hundreds of histone mark and open chromatin datasets from a variety of cell lines, primary cells, and tissues, and comparing these features along with matched DNA methylation and gene expression data, TENET identifies TFs and REs linked to a specific cell type. Moreover, we developed methods to interrogate findings using motifs, clinical information, and other genomic and chromatin conformation capture datasets, and applied them to pan-cancer data, highlighting TFs and REs associated with ten different cancer types. TENET enables researchers to better characterize the three-dimensional epigenomes of cell types of interest for future clinical applications. Availability and implementation: TENET is available at http://bioconductor.org/packages/TENET. Curated functional genomic datasets utilized by TENET are available at http://bioconductor.org/packages/TENET.AnnotationHub. Example datasets are available at http://bioconductor.org/packages/TENET.ExperimentHub. Supplementary Information: Supplementary data are available at Bioinformatics online.
- 1 August 2025
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 41 (8)
Open AccessTracing regulatory element networks using epigenetic traits to identify key transcription factors: TENET R/Bioconductor package
Summary: There is a lack of publicly available bioinformatic tools that can be widely used by researchers to identify transcription factors (TFs) that regulate cell type-specific regulatory elements (REs). To address this, we developed the Tracing regulatory Element Networks using Epigenetic Traits (TENET) R/Bioconductor package. By collecting hundreds of histone mark and open chromatin datasets from a variety of cell lines, primary cells, and tissues, and comparing these features along with matched DNA methylation and gene expression data, TENET identifies TFs and REs linked to a specific cell type. Moreover, we developed methods to interrogate findings using motifs, clinical information, and other genomic and chromatin conformation capture datasets, and applied them to pan-cancer data, highlighting TFs and REs associated with ten different cancer types. TENET enables researchers to better characterize the three-dimensional epigenomes of cell types of interest for future clinical applications. Availability and implementation: TENET is available at http://bioconductor.org/packages/TENET. Curated functional genomic datasets utilized by TENET are available at http://bioconductor.org/packages/TENET.AnnotationHub. Example datasets are available at http://bioconductor.org/packages/TENET.ExperimentHub. Supplementary Information: Supplementary data are available at Bioinformatics online.